A Phase 3 interventional study of MEDI4736 and Tremelimumab in Squamous Cell Carcinoma of the Head and Neck, sponsored by AstraZeneca. Completed at 197 sites in 23 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2021-10-13.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing durvalumab in Squamous Cell Carcinoma of Head and Neck — none open to participants now, 3 under way, none of them phase 3. durvalumab · Squamous Cell Carcinoma of Head and Neck.
Among the 20 studies testing durvalumab in Squamous Cell Carcinoma of Head and Neck, this one has the largest enrollment, is the only one that started in 2015, is one of 2 in phase 3, and was the 3rd registered.
2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.
Browse Squamous Cell Carcinoma of Head and Neck studies →None of the 20 studies testing durvalumab in Squamous Cell Carcinoma of Head and Neck is open now. The open studies under Squamous Cell Carcinoma of Head and Neck, anywhere →
durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, durvalumab is the treatment under test here. Read study by study →
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 11 · Phase 3 3
First in 2013; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 823 is above the median of 48 across 1,653 interventional studies indexed under Squamous Cell Carcinoma of Head and Neck.
Median enrollment 40 across the 20 interventional studies. Of the 16 that completed or were terminated, 4 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 20 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
22 studies in Squamous Cell Carcinoma of Head and Neck by AstraZeneca: 4 open now, 6 under way, 2 of them phase 3. Of 15 finished, 5 (33%) have results posted.
Among the 22 studies in Squamous Cell Carcinoma of Head and Neck by AstraZeneca, this one is the 2nd largest by enrollment of the 21 interventional ones that give a count, is one of 4 that started in 2015, is one of 4 in phase 3, and was the 9th registered.
AstraZeneca’s Squamous Cell Carcinoma of Head and Neck studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing durvalumab in Squamous Cell Carcinoma of Head and Neck, from their registry updates:
Among AstraZeneca’s 22 in Squamous Cell Carcinoma of Head and Neck:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, open-label, multi-center, 3-arm, global Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination or MEDI4736 monotherapy versus SoC (EXTREME regimen) in the treatment of patients with SCCHN who have not received prior systemic chemotherapy for recurrent or metastatic disease.
Patients will be randomized in a 2:1:1 ratio to MEDI4736 + tremelimumab combination therapy, MEDI4736 monotherapy, or SoC. Patients in all arms will continue therapy until progression. Tumor assessments will be performed on computed tomography scans or magnetic resonance imaging scans, preferably with intravenous (IV) contrast. Efficacy for all patients will be assessed by objective tumor assessments every 6 weeks for the first 24 weeks, then every 8 weeks thereafter until treatment discontinuation due to progression or toxicity. All patients will be followed every 3 months for survival after progression is confirmed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MEDI4736 monotherapy.
Biological: MEDI4736
MEDI4736+Tremelimumab combination therapy
Biological: Tremelimumab · Biological: MEDI4736+Tremelimumab
Standard of Care treatment
Biological: Cetuximab · Drug: 5-fluorouracil (5FU) · Drug: Cisplatin · Drug: Carboplatin
Anti-PD-L1 antibody
Anti-CTLA-4 Antibody
Drug pages: Durvalumab · Tremelimumab
Monoclonal Antibody
Chemotherapy Agent
Chemotherapy agent
Chemotherapy Agent
Overall Survival (OS) Status in the PD-L1 TC/IC High Subgroup - Durvalumab Versus Standard of Care (SOC)
Number of participants with Overall Survival (OS)
Time frame: From date of randomization until time of final analysis, an average of approximately 4 years
Overall Survival (OS) Median Duration in the PD-L1 TC/IC High Subgroup
Time from the date of randomization until death due to any cause (i.e., date of death or censoring - date of randomization + 1)
Time frame: From date of randomization until time of final analysis, an average of approximately 4 years
Overall Survival (OS) Status in the PD-L1 TC/IC High Subgroup - Durvalumab + Tremelimumab Versus Standard of Care (SOC)
Number of participants with Overall Survival (OS)
Time frame: From date of randomization until time of final analysis, an average of approximately 4 years
Percentage of Patients Alive at 12, 18 and 24 Months in the PD-L1 TC/IC High Subgroup
Percentage of patients alive
Time frame: 12, 18 and 24 months after randomization
Progression Free Survival (PFS) in the PD-L1 TC/IC High Subgroup
Time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression). Progression is defined using Response Evaluation Criteria in Solid Tumours criteria (RECIST v1.1), as ≥20% increase in the sum of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions
Time frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter, up to approximately 4 years
Objective Response Rate (ORR) in the PD-L1 TC/IC High Subgroup
Number (%) of patients with at least 1 visit response of complete response (CR) or partial response (PR). Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) for target lesions (TL) and assessed by MRI or CT: CR: Disappearance of all TLs since baseline; PR: \>= 30% decrease in the sum of diameters of TLs; Overall Response (OR = CR + PR)
Time frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter, up to approximately 4 years
Duration of Response (DoR) in the PD-L1 TC/IC High Subgroup
Time from the date of first documented response until the first date of documented progression or death in the absence of disease progression
Time frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter, up to approximately 4 years
Overall Survival (OS) Status in the All-comers (Full Analysis Set)
Number of participants with Overall Survival (OS)
Time frame: From date of randomization until time of final analysis, an average of approximately 4 years
Overall Survival (OS) Median Duration in the All-comers (Full Analysis Set)
Time from the date of randomization until death due to any cause (i.e., date of death or censoring - date of randomization + 1)
Time frame: From date of randomization until time of final analysis, an average of approximately 4 years
Percentage of Patients Alive at 12, 18 and 24 Months in the All-comers (Full Analysis Set)
Percentage of patients alive
Time frame: 12, 18 and 24 months after randomization
Progression Free Survival (PFS) in the All-comers (Full Analysis Set)
Time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression). Progression is defined using Response Evaluation Criteria in Solid Tumours criteria (RECIST v1.1), as ≥20% increase in the sum of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions
Time frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter, up to approximately 4 years
Objective Response Rate (ORR) in the All-comers (Full Analysis Set)
Number (%) of patients with at least 1 visit response of complete response (CR) or partial response (PR). Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) for target lesions (TL) and assessed by MRI or CT: CR: Disappearance of all TLs since baseline; PR: \>= 30% decrease in the sum of diameters of TLs; Overall Response (OR = CR + PR)
Time frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter, up to approximately 4 years
Duration of Response (DoR) in the All-comers (Full Analysis Set)
Time from the date of first documented response until the first date of documented progression or death in the absence of disease progression
Time frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter, up to approximately 4 years
Patients meeting all the eligibility criteria were randomized 2:1:1 to durvalumab plus tremelimumab combination therapy, durvalumab monotherapy or standard of care.
| Milestone | Durvalumab + Tremelimumab | Durvalumab | Standard of Care (SOC) |
|---|---|---|---|
| Started | 413 | 204 | 206 |
| Full analysis set | 413 | 204 | 206 |
| Safety analysis set | 408 | 202 | 196 |
| Pd-l1 tc/ic high subgroup analysis set | 190 | 99 | 94 |
| Completed | 0 | 0 | 0 |
| Not completed | 413 | 204 | 206 |
| Withdrew: Death | 352 | 174 | 161 |
| Withdrew: Withdrawal by subject | 8 | 5 | 16 |
| Withdrew: Patients alive or lost to follow-up at dco | 53 | 25 | 29 |
Number of participants with Overall Survival (OS)
| Participants | Durvalumab + Tremelimumab | Durvalumab | Standard of Care (SOC) |
|---|---|---|---|
| Death | 162 | 84 | 77 |
| Voluntary Discontinuation by subject | 1 | 1 | 3 |
| Alive or lost to follow up | 27 | 14 | 14 |
Time from the date of randomization until death due to any cause (i.e., date of death or censoring - date of randomization + 1)
| Months | Durvalumab + Tremelimumab | Durvalumab | Standard of Care (SOC) |
|---|---|---|---|
| Overall Survival (OS) Median Duration in the PD-L1 TC/IC High Subgroup | 11.2 (9.5 to 13.9) | 10.9 (9.0 to 14.3) | 10.9 (8.3 to 13.4) |
Number of participants with Overall Survival (OS)
| Participants | Durvalumab + Tremelimumab | Durvalumab | Standard of Care (SOC) |
|---|---|---|---|
| Overall Survival (OS) Status in the PD-L1 TC/IC High Subgroup - Durvalumab + Tremelimumab Versus Standard of Care (SOC) | 162 | 84 | 77 |
Percentage of patients alive
| % of participants | Durvalumab + Tremelimumab | Durvalumab | Standard of Care (SOC) |
|---|---|---|---|
| at 12 months | 49.3 (42.0 to 56.2) | 48.0 (37.8 to 57.4) | 44.0 (33.6 to 53.8) |
| at 18 months | 31.8 (25.3 to 38.5) | 34.7 (25.5 to 44.1) | 30.8 (21.6 to 40.4) |
| at 24 months | 23.9 (18.0 to 30.1) | 27.6 (19.2 to 36.6) | 26.4 (17.8 to 35.7) |
Time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression). Progression is defined using Response Evaluation Criteria in Solid Tumours criteria (RECIST v1.1), as ≥20% increase in the sum of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions
| Months | Durvalumab + Tremelimumab | Durvalumab | Standard of Care (SOC) |
|---|---|---|---|
| Progression Free Survival (PFS) in the PD-L1 TC/IC High Subgroup | 2.8 (2.6 to 3.3) | 2.8 (1.7 to 4.2) | 5.3 (4.3 to 5.8) |
Number (%) of patients with at least 1 visit response of complete response (CR) or partial response (PR). Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) for target lesions (TL) and assessed by MRI or CT: CR: Disappearance of all TLs since baseline; PR: \>= 30% decrease in the sum of diameters of TLs; Overall Response (OR = CR + PR)
| Participants | Durvalumab + Tremelimumab | Durvalumab | Standard of Care (SOC) |
|---|---|---|---|
| Response | 48 | 16 | 47 |
| No response | 142 | 83 | 47 |
Time from the date of first documented response until the first date of documented progression or death in the absence of disease progression
| Months | Durvalumab + Tremelimumab | Durvalumab | Standard of Care (SOC) |
|---|---|---|---|
| Duration of Response (DoR) in the PD-L1 TC/IC High Subgroup | 6.5 (4.5 to 16.1) | 12.3 (5.6 to NA) | 4.2 (3.0 to 5.7) |
Number of participants with Overall Survival (OS)
| Participants | Durvalumab + Tremelimumab | Durvalumab | Standard of Care (SOC) |
|---|---|---|---|
| Death | 356 | 176 | 171 |
| Voluntary Discontinuation by subject | 4 | 3 | 6 |
| Alive or lost to follow up | 53 | 25 | 29 |
Time from the date of randomization until death due to any cause (i.e., date of death or censoring - date of randomization + 1)
| Months | Durvalumab + Tremelimumab | Durvalumab | Standard of Care (SOC) |
|---|---|---|---|
| Overall Survival (OS) Median Duration in the All-comers (Full Analysis Set) | 10.7 (9.6 to 12.2) | 9.9 (8.9 to 11.9) | 10.3 (9.0 to 12.1) |
Percentage of patients alive
| % of participants | Durvalumab + Tremelimumab | Durvalumab | Standard of Care (SOC) |
|---|---|---|---|
| at 12 months | 46.5 (41.6 to 51.2) | 42.8 (35.9 to 49.5) | 43.8 (36.8 to 50.5) |
| at 18 months | 30.7 (26.3 to 35.2) | 31.2 (24.9 to 37.7) | 29.7 (23.5 to 36.1) |
| at 24 months | 22.9 (18.9 to 27.0) | 24.7 (18.9 to 30.8) | 23.2 (17.6 to 29.2) |
Time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression). Progression is defined using Response Evaluation Criteria in Solid Tumours criteria (RECIST v1.1), as ≥20% increase in the sum of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions
| Months | Durvalumab + Tremelimumab | Durvalumab | Standard of Care (SOC) |
|---|---|---|---|
| Progression Free Survival (PFS) in the All-comers (Full Analysis Set) | 2.8 (2.6 to 2.9) | 2.8 (2.0 to 2.8) | 5.4 (4.4 to 5.7) |
Number (%) of patients with at least 1 visit response of complete response (CR) or partial response (PR). Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) for target lesions (TL) and assessed by MRI or CT: CR: Disappearance of all TLs since baseline; PR: \>= 30% decrease in the sum of diameters of TLs; Overall Response (OR = CR + PR)
| Participants | Durvalumab + Tremelimumab | Durvalumab | Standard of Care (SOC) |
|---|---|---|---|
| Response | 90 | 35 | 101 |
| No response | 323 | 169 | 105 |
Time from the date of first documented response until the first date of documented progression or death in the absence of disease progression
| Months | Durvalumab + Tremelimumab | Durvalumab | Standard of Care (SOC) |
|---|---|---|---|
| Duration of Response (DoR) in the All-comers (Full Analysis Set) | 9.2 (6.0 to 19.6) | 11.9 (4.6 to 17.8) | 4.2 (3.7 to 4.5) |
Collected over Adverse events and serious adverse events will be collected from the time of signature of informed consent throughout the treatment period and including the follow-up period (up to 90 days after the last dose of investigational product or until initiation of another therapy) for an average of approximately 4 years.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Durvalumab + Tremelimumab | 356/413 (86.2%) | 168/408 (41.2%) | 317/408 (77.7%) |
| Durvalumab | 176/204 (86.3%) | 78/202 (38.6%) | 153/202 (75.7%) |
| Standard of Care (SOC) | 171/206 (83%) | 94/196 (48%) | 182/196 (92.9%) |
| Event | Durvalumab + Tremelimumab | Durvalumab | Standard of Care (SOC) |
|---|---|---|---|
| PneumoniaInfections and infestations | 32/408 | 14/202 | 13/196 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/408 | 0/202 | 8/196 |
| Tumour haemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 5/408 | 7/202 | 0/196 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/408 | 0/202 | 5/196 |
| NeutropeniaBlood and lymphatic system disorders | 1/408 | 1/202 | 5/196 |
| DysphagiaGastrointestinal disorders | 6/408 | 1/202 | 5/196 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 2/408 | 0/202 | 5/196 |
| DiarrhoeaGastrointestinal disorders | 9/408 | 2/202 | 4/196 |
| Mucosal inflammationGeneral disorders | 0/408 | 0/202 | 4/196 |
| LeukopeniaBlood and lymphatic system disorders | 0/408 | 0/202 | 4/196 |
| Event | Durvalumab + Tremelimumab | Durvalumab | Standard of Care (SOC) |
|---|---|---|---|
| RashSkin and subcutaneous tissue disorders | 50/408 | 17/202 | 81/196 |
| NauseaGastrointestinal disorders | 52/408 | 13/202 | 74/196 |
| AnaemiaBlood and lymphatic system disorders | 61/408 | 22/202 | 65/196 |
| NeutropeniaBlood and lymphatic system disorders | 2/408 | 0/202 | 63/196 |
| DiarrhoeaGastrointestinal disorders | 70/408 | 15/202 | 60/196 |
| FatigueGeneral disorders | 66/408 | 35/202 | 56/196 |
| ConstipationGastrointestinal disorders | 59/408 | 24/202 | 54/196 |
| Decreased appetiteMetabolism and nutrition disorders | 52/408 | 20/202 | 46/196 |
| HypomagnesaemiaMetabolism and nutrition disorders | 11/408 | 3/202 | 45/196 |
| Mucosal inflammationGeneral disorders | 15/408 | 6/202 | 43/196 |
| Age, Continuous(Years) | Durvalumab + Tremelimumab | Durvalumab | Standard of Care (SOC) | Total |
|---|---|---|---|---|
| Mean | 60.5 ± 9.56 | 60.2 ± 10.41 | 60.9 ± 9.45 | 60.5 ± 9.74 |
| Sex: Female, Male(Participants) | Durvalumab + Tremelimumab | Durvalumab | Standard of Care (SOC) | Total |
|---|---|---|---|---|
| Female | 73 | 29 | 32 | 134 |
| Male | 340 | 175 | 174 | 689 |
| Race/Ethnicity, Customized(Participants) | Durvalumab + Tremelimumab | Durvalumab | Standard of Care (SOC) | Total |
|---|---|---|---|---|
| White | 298 | 145 | 160 | 603 |
| Black or African American | 5 | 3 | 2 | 10 |
| Asian | 109 | 54 | 42 | 205 |
| Other | 0 | 2 | 2 | 4 |
| Missing | 1 | 0 | 0 | 1 |
Showing the first 100 of 197 sites across 23 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Oct 2015 to primary completion in Jul 2020, 56 months.
Results were first posted in Oct 2021, 1 year 3 months after primary completion.
Of 78 phase 3 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 117. This study's 56 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Durvalumab · Tremelimumab
Squamous Cell Carcinoma of Head and Neck →